Correction: Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.

Autor: Northcott J; Personalis, Inc., Fremont, CA 94555, USA., Bartha G; Personalis, Inc., Fremont, CA 94555, USA., Harris J; Personalis, Inc., Fremont, CA 94555, USA., Li C; Personalis, Inc., Fremont, CA 94555, USA., Navarro FCP; Personalis, Inc., Fremont, CA 94555, USA., Pyke RM; Personalis, Inc., Fremont, CA 94555, USA., Hong M; Personalis, Inc., Fremont, CA 94555, USA., Zhang Q; Personalis, Inc., Fremont, CA 94555, USA., Ma S; Personalis, Inc., Fremont, CA 94555, USA., Chen TX; Personalis, Inc., Fremont, CA 94555, USA., Lai J; Personalis, Inc., Fremont, CA 94555, USA., Udar N; Personalis, Inc., Fremont, CA 94555, USA., Saldivar JS; Personalis, Inc., Fremont, CA 94555, USA., Ayash E; Personalis, Inc., Fremont, CA 94555, USA., Anderson J; Personalis, Inc., Fremont, CA 94555, USA., Li J; Personalis, Inc., Fremont, CA 94555, USA., Cui T; Personalis, Inc., Fremont, CA 94555, USA., Le T; Personalis, Inc., Fremont, CA 94555, USA., Chow R; Personalis, Inc., Fremont, CA 94555, USA., Velasco RJ; Personalis, Inc., Fremont, CA 94555, USA., Mallo C; Personalis, Inc., Fremont, CA 94555, USA., Santiago R; Personalis, Inc., Fremont, CA 94555, USA., Bruce RC; Personalis, Inc., Fremont, CA 94555, USA., Goodman LJ; Personalis, Inc., Fremont, CA 94555, USA., Chen Y; Personalis, Inc., Fremont, CA 94555, USA., Norton D; Personalis, Inc., Fremont, CA 94555, USA., Chen RO; Personalis, Inc., Fremont, CA 94555, USA.; Co-last authors., Lyle JM; Personalis, Inc., Fremont, CA 94555, USA.; Co-last authors.

Publikováno v: Oncotarget [Oncotarget] 2024 Jun 20; Vol. 15, pp. 407. Date of Electronic Publication: 2024 Jun 20.

Withdrawal of 'Precision Neoantigen Discovery Using Large-scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation'.

Autor: Pyke RM; Personalis, Inc, Menlo Park, California, USA., Mellacheruvu D; Personalis, Inc, Menlo Park, California, USA., Dea S; Personalis, Inc, Menlo Park, California, USA., Abbott CW; Personalis, Inc, Menlo Park, California, USA., Zhang SV; Personalis, Inc, Menlo Park, California, USA., Phillips NA; Personalis, Inc, Menlo Park, California, USA., Harris J; Personalis, Inc, Menlo Park, California, USA., Bartha G; Personalis, Inc, Menlo Park, California, USA., Desai S; Personalis, Inc, Menlo Park, California, USA., McClory R; Personalis, Inc, Menlo Park, California, USA., West J; Personalis, Inc, Menlo Park, California, USA., Snyder MP; Department of Genetics, Stanford University, Palo Alto, California, USA., Chen R; Personalis, Inc, Menlo Park, California, USA., Boyle SM; Personalis, Inc, Menlo Park, California, USA. Electronic address: sean.boyle@personalis.com.

Publikováno v: Molecular & cellular proteomics : MCP [Mol Cell Proteomics] 2023 Apr; Vol. 22 (4), pp. 100511. Date of Electronic Publication: 2023 Apr 03.

A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity.

Autor: Pyke RM; Personalis, Inc, Menlo Park, CA, USA., Mellacheruvu D; Personalis, Inc, Menlo Park, CA, USA., Dea S; Personalis, Inc, Menlo Park, CA, USA., Abbott CW; Personalis, Inc, Menlo Park, CA, USA., McDaniel L; Personalis, Inc, Menlo Park, CA, USA., Bhave DP; Personalis, Inc, Menlo Park, CA, USA., Zhang SV; Personalis, Inc, Menlo Park, CA, USA., Levy E; Personalis, Inc, Menlo Park, CA, USA., Bartha G; Personalis, Inc, Menlo Park, CA, USA., West J; Personalis, Inc, Menlo Park, CA, USA., Snyder MP; Stanford University, Palo Alto, CA, USA., Chen RO; Personalis, Inc, Menlo Park, CA, USA. richard.chen@personalis.com., Boyle SM; Personalis, Inc, Menlo Park, CA, USA. sean.boyle@personalis.com.

Publikováno v: Nature communications [Nat Commun] 2022 Apr 12; Vol. 13 (1), pp. 1925. Date of Electronic Publication: 2022 Apr 12.

Withdrawn: Precision Neoantigen Discovery Using Large-scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation.

Autor: Pyke RM; Personalis, Inc, Menlo Park, California, USA., Mellacheruvu D; Personalis, Inc, Menlo Park, California, USA., Dea S; Personalis, Inc, Menlo Park, California, USA., Abbott CW; Personalis, Inc, Menlo Park, California, USA., Zhang SV; Personalis, Inc, Menlo Park, California, USA., Phillips NA; Personalis, Inc, Menlo Park, California, USA., Harris J; Personalis, Inc, Menlo Park, California, USA., Bartha G; Personalis, Inc, Menlo Park, California, USA., Desai S; Personalis, Inc, Menlo Park, California, USA., McClory R; Personalis, Inc, Menlo Park, California, USA., West J; Personalis, Inc, Menlo Park, California, USA., Snyder MP; Department of Genetics, Stanford University, Palo Alto, California, USA., Chen R; Personalis, Inc, Menlo Park, California, USA., Boyle SM; Personalis, Inc, Menlo Park, California, USA. Electronic address: sean.boyle@personalis.com.

Publikováno v: Molecular & cellular proteomics : MCP [Mol Cell Proteomics] 2021; Vol. 20, pp. 100111. Date of Electronic Publication: 2021 Jun 12.

MHC-I genotype and tumor mutational burden predict response to immunotherapy.

Autor: Goodman AM; Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA. a1goodman@ucsd.edu.; Division of Hematology/Oncology Center for Personalized Cancer Therapy, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA. a1goodman@ucsd.edu.; UC San Diego Moores Cancer Center, 855 Health Sciences Drive, La Jolla, CA, 92093-0658, USA. a1goodman@ucsd.edu., Castro A; Division of Medical Genetics, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.; Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA, 92093, USA.; Health Science, Department of Biomedical Informatics, School of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA., Pyke RM; Division of Medical Genetics, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.; Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA, 92093, USA., Okamura R; Division of Hematology/Oncology Center for Personalized Cancer Therapy, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA., Kato S; Division of Hematology/Oncology Center for Personalized Cancer Therapy, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.; UC San Diego Moores Cancer Center, 855 Health Sciences Drive, La Jolla, CA, 92093-0658, USA., Riviere P; Division of Hematology/Oncology Center for Personalized Cancer Therapy, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA., Frampton G; Foundation Medicine, Cambridge, MA, 02141, USA., Sokol E; Foundation Medicine, Cambridge, MA, 02141, USA., Zhang X; Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, 92093, USA., Ball ED; Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.; UC San Diego Moores Cancer Center, 855 Health Sciences Drive, La Jolla, CA, 92093-0658, USA., Carter H; Division of Medical Genetics, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.; Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA, 92093, USA.; CIFAR, MaRS Centre, West Tower, 661 University Ave., Suite 505, Toronto, ON, M5G 1M1, Canada., Kurzrock R; Division of Hematology/Oncology Center for Personalized Cancer Therapy, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.; UC San Diego Moores Cancer Center, 855 Health Sciences Drive, La Jolla, CA, 92093-0658, USA.

Publikováno v: Genome medicine [Genome Med] 2020 May 19; Vol. 12 (1), pp. 45. Date of Electronic Publication: 2020 May 19.